Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;70(3):666-75.
doi: 10.1227/NEU.0b013e318236a809.

Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury

Stefania Mondello  1 , Akinyi Linnet, Andras Buki, Steven Robicsek, Andrea Gabrielli, Joseph Tepas, Linda Papa, Gretchen M Brophy, Frank Tortella, Ronald L Hayes, Kevin K Wang
Affiliations

Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury

Stefania Mondello et al. Neurosurgery. 2012 Mar.

Abstract

Background: Brain damage markers released in cerebrospinal fluid (CSF) and blood may provide valuable information about diagnosis and outcome prediction after traumatic brain injury (TBI).

Objective: To examine the concentrations of ubiquitin C-terminal hydrolase-L1 (UCH-L1), a novel brain injury biomarker, in CSF and serum of severe TBI patients and their association with clinical characteristics and outcome.

Methods: This case-control study enrolled 95 severe TBI subjects (Glasgow Coma Scale [GCS] score, 8). Using sensitive UCH-L1 sandwich ELISA, we studied the temporal profile of CSF and serum UCH-L1 levels over 7 days for severe TBI patients.

Results: Comparison of serum and CSF levels of UCH-L1 in TBI patients and control subjects shows a robust and significant elevation of UCH-L1 in the acute phase and over the 7-day study period. Serum and CSF UCH-L1 receiver-operating characteristic curves further confirm strong specificity and selectivity for diagnosing severe TBI vs controls, with area under the curve values in serum and CSF statistically significant at all time points up to 24 hours (P < .001). The first 12-hour levels of both serum and CSF UCH-L1 in patients with GCS score of 3 to 5 were also significantly higher than those with GCS score of 6 to 8. Furthermore, UCH-L1 levels in CSF and serum appear to distinguish severe TBI survivors from nonsurvivors within the study, with nonsurvivors having significantly higher and more persistent levels of serum and CSF UCH-L1. Cumulative serum UCH-L1 levels > 5.22 ng/mL predicted death (odds ratio, 4.8).

Conclusion: Serum levels of UCH-L1 appear to have potential clinical utility in diagnosing TBI, including correlating to injury severity and survival outcome.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

Drs. Mondello, Buki, Robicsek, Gabrielli, Brophy and Papa are consultants of Banyan Biomarkers, Inc.; Ms. Akinyi is employee of Banyan Biomarkers, Inc.; Drs. Wang and Hayes own stock, receive royalties from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication. Dr. Tortella reports no disclosures.

Figures

Fig. 1
Fig. 1. Characterization of UCH-L1 antigen calibrator, capture and detection antibodies and sandwich ELISA performance
(A) Recombinant His-tag human UCH-L1 (20 μg) from E. coli was analyzed by SDS-electrophoresis gel stained with Coomassie blue to show proper molecular wright and purity. (B) Capture (Mouse IgM 2018) and detection (Rabbit IgG #21687) antibodies were charactrerized by their specific recognition of recombinant human UCH-L1 (100 ng; see above) and native human UCH-L1 target in human brain vs. other organ lysates (20 μg). (C) Optimized sandwich ELISA was subjected to performance analysis in both CSF and serum matrix. Shown were averages of accumulative data from 17 multi-day standard curve analysis. Background (no antigen) chemiluiminescent values + 3 x SD were also shown on Y-axis and as horizontal line. The horizontal line represents the average background chemiluminescence (no antigen) + 3 x standard deviation = 2,000 chemiluminescence units. MWM = molecular weight marker lane.
Fig. 2
Fig. 2. Temporal profile of CSF and serum UCH-L1 levels over 7 days for severe TBI patients in comparison to control subjects
Data shown are measured by ELISA. Mean ± SEM concentrations are shown. For Control subjects – only single time point samples used.
Fig. 3
Fig. 3. UCH-L1 Receiver Operation Characteristics (ROC) Curves
Comparing 24 h post injury TBI CSF (A) and serum (C) UCH-L1 level vs. CSF controls or serum normal controls, respectively. Area under the curve (AUC) over time was also plotted (B, D).
Fig. 4
Fig. 4. Comparison UCH-L1 levels in CSF (A) and in Serum (B) in survivors versus non-survivors
(over study duration and 6 hrs post-injury). *p= 0.05; Mann-Whitney U test).
Fig. 5
Fig. 5. Comparison of CSF (A) and Serum (B) levels of UCH-L1 in patients with TBI who survived versus non-survivors within 7 days from TBI
The graphs show time course of serum and CSF UCH-L1 levels in patients who survived or died. There was a marked difference between the two outcome groups. Increased initial levels of UCH-L1 and secondary increases indicate severe primary injury and the possibility of secondary brain damage associated with death.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jager TE, Weiss HB, Coben JH, Pepe PE. Traumatic brain injuries evaluated in U.S. emergency departments, 1992–1994. Acad Emerg Med. 2000;7:134–140. - PubMed
    1. TBI State Demonstration Grants. J Head Trauma Rehabil. 2000;15:750–760. - PubMed
    1. Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med. 2008;358:453–463. - PubMed
    1. Kesler SR, Adams HF, Bigler ED. SPECT, MR and quantitative MR imaging: correlates with neuropsycholgical. Brain Injury. 2000;14:851–857. - PubMed
    1. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008;25:719–738. - PMC - PubMed

Publication types

MeSH terms